Astrazeneca PLC (NYSE:AZN) Getting Somewhat Positive Press Coverage, Report Finds

Deutsche Bank AG reduced their target price on shares of AstraZeneca plc from GBX 5,700 ($74.23) to GBX 5,300 ($69.02) and set a "buy" rating for the company in a research report on Thursday, August 3rd.

AstraZeneca plc (LON:AZN) traded up 0.74% on Friday, reaching GBX 4564.00. AstraZeneca PLC had 519 analyst reports since July 23, 2015 according to SRatingsIntel. The company has a 50-day moving average price of $33.57 and a 200 day moving average price of $31.37.

COPYRIGHT VIOLATION WARNING: "Sanders Morris Harris LLC Holds Stake in Astrazeneca PLC (NYSE:AZN)" was originally published by BNB Daily and is the property of of BNB Daily.

A number of equities research analysts have recently commented on AZN shares. HSBC Holdings plc reiterated a reduce rating and set a GBX 4,200 ($54.69) target price on shares of AstraZeneca plc in a report on Friday, May 5th. Puzo Michael J sold 11,625 shares as Pembina Pipeline Co (PBA)'s stock declined 0.40%. AstraZeneca plc presently has an average rating of "Hold" and a consensus price target of GBX 4,956.48 ($64.55). Hayek Kallen Investment Management acquired a new position in shares of Astrazeneca PLC during the second quarter worth approximately $211,000. If you are reading this report on another website, it was copied illegally and reposted in violation of United States & global copyright and trademark law. The Premier Asset Managment Llc holds 30,160 shares with $823,000 value, down from 45,760 last quarter.

Other analysts have also recently issued research reports about the company. Quadrant Capital Group LLC now owns 4,591 shares of the company's stock valued at $138,000 after buying an additional 2,805 shares in the last quarter. 1,857,621 shares of the company were exchanged. Astrazeneca PLC has a 52-week low of 25.55 and a 52-week high of 35.60. The firm has a market cap of $76.11 billion, a PE ratio of 19.72 and a beta of 0.74. Goldman Sachs Group, Inc. Finally, Leerink Swann reissued an "outperform" rating and issued a $36.00 price objective (up from $33.00) on shares of Astrazeneca PLC in a report on Wednesday, May 17th.

Among 24 analysts covering Diageo (NYSE:DEO), 16 have Buy rating, 3 Sell and 5 Hold. The company now has an average rating of Hold and a consensus price target of GBX 209.39 ($2.73). This represents a dividend yield of 1.35%. The legal version of this article can be read at https://transcriptdaily.com/2017/08/08/astrazeneca-plc-lonazn-price-target-cut-to-gbx-4700-by-analysts-at-credit-suisse-group-updated.html. Astrazeneca PLC's dividend has Aug 11, 2017 as record date. Astrazeneca PLC's payout ratio is 44.92%.

John Hancock Hedged Equity & Income Fund is a diversified, closed-end management investment company.

Centrica plc is an energy and services company. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. Cowen and Company reissued a "hold" rating and issued a $34.00 price objective on shares of Astrazeneca PLC in a research report on Friday, July 28th. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Latest News